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The long-term risk of malignancy associated with
stem cell therapies is a significant concern in the
clinical application of this exciting technology. We
report a cancer-selective strategy to enhance the
safety of stem cell therapies. Briefly, using a cell
engineering approach, we show that aggressive
cancers derived from human or murine induced
pluripotent stem cells (iPSCs) and embryonic stem
cells (ESCs) are strikingly sensitive to temporary
MYC blockade. On the other hand, differentiated tis-
sues derived from human or mouse iPSCs can
readily tolerate temporary MYC inactivation. In can-
cer cells, endogenous MYC is required to maintain
the metabolic and epigenetic functions of the em-
bryonic and cancer-specific pyruvate kinase M2
isoform (PKM2). In summary, our results implicate
PKM2 in cancer’s increased MYC dependence and
indicate dominant MYC inhibition as a cancer-selec-
tive fail-safe for stem cell therapies.INTRODUCTION
Tissues derived from pluripotent stem cells (PSCs) cells have
great potential in regenerative medicine and can, in principle,
replace any differentiated tissue (Hanna et al., 2007; Takahashi
and Yamanaka, 2006). Recent successes include the generation
of retinal cells (Osakada et al., 2009), functional liver tissue
(Takebe et al., 2013), and dopaminergic neurons (Kriks et al.,
2011). These strategies are approaching clinical testing, but
the risk of iatrogenic malignancy remains a significant concern
(Goldring et al., 2011; Lee et al., 2013). For example, cancers
develop with increased frequency in induced pluripotent stem
(iPS) cell-chimeric animals (Carey et al., 2010; Okita et al.,
2007; Stadtfeld et al., 2010b), and neuronal tumors occur in pri-Cell Remates injected with PSC-derived neurogenic cells (Doi et al.,
2012). Most dramatically, an ataxia telangiectasia patient devel-
opedmultifocal aggressive brain cancer following administration
of neurogenic stem cells (Amariglio et al., 2009). These citations
illustrate a need for effective and cancer-selective fail-safe
mechanisms.
The causes of malignancy are not entirely clear. Reactivation
of reprogramming factors, especially the MYC oncogene, has
been implicated (Okita et al., 2007). However, cancers also
occurred, albeit with lower frequency, when MYC was omitted
form reprogramming protocols (Miura et al., 2009; Nakagawa
et al., 2008; Werbowetski-Ogilvie et al., 2009). Notably, malig-
nant and pluripotent cells show increased genomic instability,
frequent and nonrandom chromosomal aberrations, and recur-
rent inactivation of canonical tumor-suppressor genes (Hussein
et al., 2011;Mario´n et al., 2009; Mayshar et al., 2010). These find-
ings suggest that initial barriers to transformation may be fortu-
itously inactivated in PSC and derived tissues.
Improved reprogramming procedures have greatly reduced,
but not eliminated, the risk of cancer (Lee et al., 2013). These
include nonintegrating and excisable vectors, the exclusion
of MYC, and reprogramming by RNA, protein, or small mole-
cules (Carey et al., 2010; Kaji et al., 2009; Stadtfeld et al.,
2010a; Wernig et al., 2008). Additional strategies seek to purge
residual PSCs, genomic surveys for somatic mutations, and
conventional suicide genes (Choo et al., 2008; Tan et al.,
2009). In this study, we explore a strategy based on recent
insight into cancer’s ‘‘oncogene dependence’’ (Jain et al.,
2002; Soucek et al., 2008; Weinstein, 2002). We show that
introduction of a dominant-negative MYC construct and
temporary MYC inactivation can destroy aggressive iPS and
embryonic stem (ES) cell-derived cancers while sparing healthy
PSC-derived tissues.
RESULTS
To explore the MYC dependence of PSC-derived tissues, we
introduced a dominant-negative MYC allele into karyotypicallyports 8, 1677–1685, September 25, 2014 ª2014 The Authors 1677
normal human and murine PSCs (Figure 1A). Briefly, OmomycER
is an inducible dominant-negative MYC allele that is uniquely
able to form inactive dimers with all three endogenous MYC pro-
teins and does not bind other helix-loop-helix factors (Savino
et al., 2011; Soucek et al., 1998). We reprogrammed human
and murine fibroblasts using a single excisable polycistronic
construct or four separate vectors, respectively (Papapetrou
et al., 2011). We confirmed reprogramming by immunofluores-
cence for NANOG and showed loss of the exogenous construct
by fluorescence-activated cell sorting and PCR (Figures S1A–
S1C). We isolated karyotypically normal clones and introduced
Omomyc along with a citrine reporter into both human iPS and
murine iPS and ESCs (Figures S1D–S1E).
Murine iPSCs deficient for the p53 tumor suppressor give rise
to aggressive embryonal carcinomas. Briefly, the p53 tumor
suppressor restricts reprogramming and p53-deficient murine
fibroblast formed iPSC colonies faster than wild-type cells
(Figure S1F) (Hong et al., 2009; Mario´n et al., 2009). Upon trans-
plantation, the p53/ iPSCs rapidly formed aggressive cancers
(p53+/+: n = 5; p53/: n = 5; latency to 1 cm3 tumor p < 0.001)
(Figure S1G). Pathologically, these cancers resembled primitive
embryonal carcinomas (EC), composed of immature OCT4- and
CD30-negative tissues with some SALL4 expression (28% ±
11% [mean ± SD]), a high proliferation index by Ki67 (34.6% ±
6%), and little apoptosis by TUNEL (14.2% ± 10%) (Figure S1H).
Notably, the humanMYC transgene was not reactivated in these
cancers, and instead we observed elevated expression of the
endogenous Myc mRNA (Figure S1I).
Temporary MYC blockade produced dramatic regression in
aggressive iPSC-derived embryonal carcinomas. We initiated
tamoxifen (TAM) treatment when tumors reached 1 cm3 (TAM:
10 mg/ml, alternate days for 2 weeks). This treatment caused
the OmomycER-expressing cancers (left flank) to collapse
whereas control tumors (right flank) continued to grow (nOmo =
5, nControl = 5, p < 0.005) (Figures 1B–1D). After TAM treatment,
we retrieved a residual cystic mass containing cartilaginous ma-
terial, large areas of TUNEL-positive apoptosis, and some
SALL4-positive and Ki67-negative cells indicating yolk sac dif-
ferentiation and absence of proliferation (OmomycER versus
control: SALL4: 92.3% ± 19% versus 28.7% ± 14%, p < 0.05;
TUNEL: 41.2% ± 13% versus 14.2% ± 10%; p < 0.05; Ki67:
34.6% ± 6% versus 24.2% ± 10%) (Figure 1E; Figure S1J).
We confirmed these observations using murine ESCs ex-
pressing a p53 short-hairpin RNA to ensure these results did
not reflect specific properties of the iPSCs. Briefly, cancers
derived from ES cells were pathologically indistinguishable
from cancers derived from iPSCs (Figures S1K–S1M). They re-
sponded in exactly the same manner to OmomycER activation
(Figures S1N–S1P). Hence, aggressive and p53-deficient can-
cers derived from PSCs strictly depend on the continuous
activity of endogenous MYC.
Next, we tested the effect ofMYC inactivation onwell-differen-
tiated, benign teratomas. Briefly, p53 wild-type iPS and ESCs
give rise to typical teratomas composed of several different
germ cell layers including cartilage and neuronal and glial tissues
that lacked the pluripotency markers CD30 and OCT4 and con-
tained a few SALL4-positive cells indicating early yolk sac differ-
entiation (11.8% ± 7% [mean ± SD]) (Figures S1Q, S1U, and1678 Cell Reports 8, 1677–1685, September 25, 2014 ª2014 The AuS1V). As seen with the aggressive embryonal carcinomas, the
iPSC-derived teratomas showed no expression of the exoge-
nous MYC, and instead the endogenous Myc mRNA was
modestly increased (Figures S1R and S1S). OmomycER induc-
tion using the same protocol as before produced no measurable
effect on iPS or ESC-derived teratomas (nOmo = 6, ncontrol = 6;
p = 0.7) (Figures S1T, S1U, and S1W–S1Z) and showed no differ-
ence in proliferation or apoptosis by Ki67 and TUNEL stains,
respectively (control versus Omomyc: Ki67: 8.7% ± 5% versus
9.1% ± 2.5%; p > 0.05; TUNEL 5.6% ± 3.6% versus 3.6% ±
2%; p > 0.05). Hence, differentiated teratomas no longer depend
on MYC and are insensitive to MYC blockade.
Potentially, MYC blockade can be used to purge in vitro cul-
tures form residual iPSCs and to prevent tumor growth. To test
these possibilities we first activated omomyc in iPSC cultures
and observed rapid induction of cell death consistent with the
notion that MYC is required to maintain these pluripotent cells
(Figures S1A1 and S1B1) (Cartwright et al., 2005). We also tested
whether Omomycmight be able to delay or prevent tumor forma-
tion in vivo. Briefly, we activated OmomycER shortly following
transplantation, and this could significantly reduce teratoma for-
mation in vivo (iPS OmomycER untreated n = 4, iPS OmomycER
tamoxifen [10 mg/ml] n = 4, p = 0.02) (Figures S1C1 and
S1D1). Hence, OmomycER can effectively purge residual tumor-
igenic iPSCs.
Next, we wanted to explore the effect of temporary MYC inac-
tivation on healthy iPSC-derived tissues in vivo. We generated
chimeric animals from iPSCs transduced with OmomycER to
test the effect of temporary MYC inactivation in a physiological
context. Briefly, we injected two clones of karyotypically normal,
iPSCs of C57B1/6J background into C57Bl/6J (B6(Cg)-Tyrc-2J/J
blastocysts and confirmed chimerism by the presence of black
coat derived from donor cells. Tamoxifen treatment (TAM,
10mg/ml on alternate days for 3 weeks) had no untoward effects
on animal health, weight, or behavior (not shown) or skin and
hair (Figure 1F). OmomycER-expressing tissues were readily
detectable by the coexpressed citrine reporter, and immunohis-
tochemistry confirmed significant contributions of iPS cells ex-
pressing omomyc (iPSOMO) before and after tamoxifen treatment
to various organs. For example, hair follicles, dermal and
epidermal structures, the upper and lower gastrointestinal tract,
the kidney, red and white pulp of spleen, and thyroid gland
showed persistent and extensive contribution of iPSOMO-derived
and citrine-positive cells and histologically intact organs after a
3-week course of systemic tamoxifen treatment (Figure 1G).
Hence, temporary MYC blockade is tolerated and does not
cause permanent disruption of iPSC-mosaic organs and tissues.
We now wanted to test this strategy in human iPSC-derived
tissues to model a clinically relevant setting. Briefly, we engi-
neered human iPSCs to express OmomycER and differentiated
these cells into neurogenic precursors (Rosette stage) and
midbrain dopaminergic neurons according to published proto-
cols (Chambers et al., 2009; Kriks et al., 2011). Intracerebral in-
jection of 2 3 105 neurogenic precursors into the striatum of
nonobese diabetic/severe combined immunodeficiency (NOD/
SCID) animals resulted in the development of brain tumors within
4weeks (tumor incidence: 9/9; vector n = 4 andOmomycER n = 5)
(Figure 2A). Histologically, these tumors resembled primitivethors
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Figure 1. Aggressive Embryonal Carcinomas
Are Sensitive to OmomycER Treatment
(A) Schematic of mouse iPS (mu iPS), ES (mu ES),
and human iPS (hu iPS) cells engineered with and
without inducible dominant-negative MYC allele
OmomycER.
(B) Animals bearing embryonal carcinomas derived
either from iPSCs expressing OmomycER (red circle)
or from control vector (blue circle) and treated with
tamoxifen (TAM).
(C and D) Comparison of tumor weights following
TAM treatment. The blue and red circles highlight
the position (D) and the size (C) of the xenografted
tumors. Error bars represent SDs, and the p value
has been calculated by a paired t test.
(E) Histopathology of primitive embryonal carci-
nomas (embryonal CA) stained as indicated.
(F) Representative chimeric animal before and after
a 3-week course of tamoxifen (TAM) treatment to
activate the dominant-negative MYC construct in
iPSC-derived tissues (the same schedule was used
in tumor treatment studies).
(G) Immunohistochemical stain for citrine identifies
tissues derived from OmomycER-expressing iPSCs
in different organ sites (panels from top): hair folli-
cles, upper gastrointestinal tract and adjacent thy-
roid gland, kidney, lower gastrointestinal tract, and
mucosal villi.
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Figure 2. Primitive Neuroectodermal Tumors
Derived from Human iPS Cells Respond to
OmomycER Activation In Vivo
(A) MRI of vector control (control) and OmomycER-
expressing PNETs before tamoxifen treatment and
at the indicated times after treatment.
(B) Tumor size measured as pixel counts on MRI
images of control and OmomycER PNETs. Error bars
represent SDs from the mean.
(C) Histology and indicated immunohistochemical
stains on control and OmomycER PNETs after
tamoxifen.
(D) Immunofluorescence stains for Ki67 and SOX2/
Nestin on OmomycER and control PNETs after
treatment.
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neuroectodermal tumors (PNETs) with islands of highly prolifer-
ative and Ki67-positive cells, invasive spread across the brain,
and expression of primitive markers (SOX2, NESTIN) in the
absence of differentiation markers (OLIG2, NeuN, synaptophy-
sin, or GFAP) (Figures S2A and S2B). Hence, we canmodel prim-
itive iPSC-derived brain tumors in vivo and recapitulate the
pathology previously seen in a patient treated with neurogenic
precursors (Amariglio et al., 2009; Doi et al., 2012).
OmomycER arrests the growth of brain cancers caused by hu-
man iPSC-derived neurogenic precursors. We initiated systemic
tamoxifen treatment to induce the OmomycER construct once
brain tumors were diagnosed by magnetic resonance imaging
(MRI) (here, ‘‘d0’’ represents the start of TAM treatment at
10 mg/ml, two times per week for 5 weeks). This treatment
blocked the expansion of OmomycER-expressing PNETs, while
PNETs-expressing a control vector continued to grow (n = 4;
p = 0.02) (Figures 2A and 2B). Histology and immunohistochem-
istry revealed complete disappearance of the Ki67-positive pro-
liferative compartment of these cancers; the treatment did not
alter tumor cell differentiation indicated by unchanged surface
marker expression (Figures 2C and 2D). Hence, MYC blockade
eliminates the growth fraction in iPSC-derived PNETs.
Next, we wondered how MYC blockade would affect differen-
tiated midbrain dopaminergic neurons in vivo. The engraftment
of 1.5 3 105 iPSC-derived neurons injected into the striatum of
NOD/SCID animals was readily discernible by MRI and subse-
quent tamoxifen treatment (using the same schedule as above)
to activate OmomycER did not affect the radiological appear-
ance control or OmomycER-expressing neurons (Figures 3A–
3D). Microscopy and immunohistochemical stains for neuronal
markers (tyrosine hydroxylase, human neural cell adhesion
molecule [hNCAM]) and a transcription factor characteristic of
dopaminergic midbrain neurons (FoxA2) confirmed equal
engraftment of morphologically intact OmomycER and control
dopaminergic neurons (Figures 3E and 3F). Together, these
data reveal a differential requirement for MYC activity in iPSC-
derived brain cancers (PNETs) that renders these tumors sensi-
tive to an inhibitory MYC allele.
What may cause this differential MYC requirement between
normal and malignant tissues? We examined how MYC contrib-
utes to the hallmark differences between normal neurons and
malignant PNETS (Figure 4A). For example, MYC has been impli-
cated in cancer-specific changes in glutamine metabolism and
mitochondrial biology (Gao et al., 2009; Zhang et al., 2012). How-
ever, we saw only modest or no difference in expression of
the glutamine transporter (SLC1A5) or the glutaminase enzyme
(GLS) between differentiated neurons and PNETs (Figures 4A–
4C; Figure S3A). Similarly, the ratio of mitochondrial to nuclear
DNA, the expression of the mitogenesis factor TFAM (Li et al.,
2005), or the cancer-associated uncoupling protein UCP2
(Zhang et al., 2011) revealed no cancer-specific changes (Fig-
ures S3B–S3D).
MYC has been implicated in the Warburg effect and aerobic
glucose metabolism (Dang et al., 2009). While we found no
change in hexokinase expression (Figure 4D), both the pyruvate
kinase isoformM2 (PKM2) and lactate dehydrogenase A (LDH-A)
were strikingly increased in PNETS compared to neurons (Fig-
ures 4E and 4F). Importantly, their expression was strictly depen-Cell Redent on MYC, and OmomycER activation resulted in near-com-
plete loss of PKM2 and LDH-A mRNA and protein expression
in PNETs (Figures 4G–4J; Figure S3E). In addition to its role in
aerobic glycolysis, PKM2 has a surprising nuclear function
and phosphorylates histone H3 to control MYC and CCND1
expression (Yang et al., 2012). Indeed, we confirm this PKM2
function in OmomycER-expressing PNETs in vivo, where TAM
treatment causes rapid loss of histone H3 (T11) phosphorylation
and reduction in the expression of the c-MYC mRNA (Figures
4K and 4L). Hence, the differential response of normal and ma-
lignant cells to MYC inactivation reflects, at least in part, the
disruption of a metabolic and epigenetic feed-forward program
(Figure 4M).
DISCUSSION
We report a strategy for enhancing the safe use of stem cells in
regenerative medicine. The propensity of PSC-derived tissues
for malignant transformation is a significant clinical concern as
highlighted by recent reports of cancer development following
the administration of neurogenic cells (Amariglio et al., 2009;
Doi et al., 2012). Continuing improvements in reprogramming
procedures, the selection of genetically suitable clones, and
different purging strategies will clearly help attenuate the risk
(Lee et al., 2013). We report an additional strategy that is
rooted in the concept of cancer’s ‘‘oncogene dependence’’
(Jain et al., 2002; Soucek et al., 2008; Weinstein, 2002). Spe-
cifically, the dominant-negative OmomycER allele provides a
unique tool to block transcriptional activation by all three
MYC proteins (Savino et al., 2011; Soucek et al., 1998, 2002,
2008). Engineering PSCs that harbor an inducible MYC inhibi-
tory allele provides a fail-safe mechanism that can be used to
(1) purge residual iPSCs (before and after engraftment), and (2)
treat aggressive cancers with a high degree of selectivity for
the malignant and rapidly proliferating cells and little or no
effect on differentiated tissues.
Our study also explores the causes underlying the differential
MYC requirement in cancer (von Eyss and Eilers, 2011). Prior
work has emphasized MYC’s role maintaining angiogenesis (So-
dir et al., 2011) and its ability to restrain cellular senescence or
differentiation (Lin et al., 2009; Varlakhanova et al., 2011; Wu
et al., 2007). Our results indicate that the differential MYC
requirement reflects, at least in part, the need to maintain the
expression of the cancer-specific isoforms of pyruvate kinase
(PKM2) and lactate dehydrogenase (LDH-A) (Christofk et al.,
2008; Clower et al., 2010; David et al., 2010; Shim et al., 1997;
Vander Heiden et al., 2009).Moreover, PKM2 is required tomain-
tain MYC expression and PKM2 loss disrupts a cancer-specific
epigenetic feed-forward mechanism (Yang et al., 2012).
EXPERIMENTAL PROCEDURES
Generation and Characterization of iPS Cells
Murine iPSCs were derived frommouse embryonic fibroblasts (MEFs) infected
with four lentiviral vectors (pLM-OCT4, pLM-Sox2, pLM-Myc, and pLM-Klf4)
expressing OCT4, SOX2, KLF4 and MYC, plated on feeder layers of mito-
mycin-C-treated embryonic fibroblasts (GlobalCells) after 96 hr.
Single ESC-like colonies were picked and expanded after 10–25 days and
cultivated on mitomycin-C-treated MEFs in KnockOut Dulbecco’s modifiedports 8, 1677–1685, September 25, 2014 ª2014 The Authors 1681
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Figure 3. Human iPSC-Derived Dopaminergic Neurons Engraft In Vivo and Tolerate OmomycER Activation
(A and C) MRI showing engraftment of control (a) and OmomycER (c) neurons following injection into the midbrain (striatum) under tamoxifen treatment (same
schedule as in tumor studies).
(B and D) Quantification of engraftment for control (B) andOmomycER-expressing (D) neurons byMRI and pixel count to determine area of engraftment. Error bars
represent SDs, and the p value has been calculated by an unpaired t test.
(E) Immunofluorescence stains of murine brain sections stained for hNCAM (green) and DAPI (blue).
(F) Immunohistochemical stains for human dopaminergic neuron markers including FOXA2, tyrosine hydroxylase, and hNCAM on control and OmomycER-ex-
pressing neurons.Eagle’s medium with high glucose (GIBCO), supplemented with 15% fetal
bovine serum (Hyclone), 0.1 mM b-mercaptoethanol, 4 mM L-glutamine, 1X
Nonessential amino acids and 1000 U/ml of leukemia inhibitory factor. Media
was changed every day. The human iPSC line thal5.10 was generated with a
single, excisable polycistronic vector expressing OCT4, KLF4, MYC, and
SOX2 (Papapetrou et al., 2011). The media were changed 24 hr later and re-
placed every day thereafter with human ESC media supplemented with
6 ng/ml FGF2 (R&D Systems) and 0.5 mM valproic acid (Sigma). A total of
15 to 25 days after transduction, colonies with human ESC morphology
were mechanically dissociated and transferred into plates preseeded with
mitomycin-C-treated MEFs (GlobalStem). Cells were thereafter passaged
with dispase and expanded to establish iPSC lines.1682 Cell Reports 8, 1677–1685, September 25, 2014 ª2014 The AuiPSC clones were characterized by immunofluorescence using anti-Nanog
Alexa 488-conjugated (eBioscience) and anti-SSEA-1 Alexa Fluor 647-conju-
gated (eBioscience). Gene expression of endogenous and transgenic Oct4,
Myc, Sox2, and Klf4 was by TaqMan quantitative RT-PCR assay.
Tumor Analysis
A total of 1 3 106 iPSCs expressing omomycER or controls were injected
subcutaneously into NOD/MrkBomTac-Prkdcscid (Taconic) mice. When the
tumors were well palpable (1 cm3), the mice were treated with 100 ml of
tamoxifen (TAM, intraperitoneal, 10 mg/ml in peanut oil). Tumors were
collected 1 week after the last treatment, weighed, and fixed in 4% formal-
dehyde for subsequent stains including hematoxylin and eosin andthors
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Figure 4. OmomycER-Sensitive Changes in
PKM2 and LDH-A Expression Distinguish
PNETs from Differentiated Neurons
(A) Quantitative RT-PCR measuring relative
expression of MYC in human iPSCs (hiPS), dopa-
minergic neurons (Neurons), and brain tumors
(PNETs).
(B–F) Quantitative RT-PCR measuring relative
expression of the indicated genes: glutamine
transporter SLC1A5) (B), glutaminase (GLS) (C),
hexokinase (D), pyruvate kinase M2 isoform
(PKM2) (E), and lactate dehydrogenase A (LDH-A)
(F).
(G and H) Quantitative RT-PCR (G) and immuno-
histochemistry (H) measuring LDH-A mRNA and
protein expression in control and OmomycER
PNETs following in vivo tamoxifen treatment.
(I and J) Quantitative RT-PCR (I) and immunohis-
tochemistry for LDH-A in control and OmomycER
PNETs following treatment.
(K) Immunohistochemical stain for histone H3
(T-11 phosphorylation) in control and OmomycER
PNETs after tamoxifen treatment in vivo.
(L) Quantitative RT-PCR measuring endogenous
MYC expression in control and OmomycER PNETs
after tamoxifen treatment in vivo. Error bars
represent SDs calculated in three independent
experiments.
(M) Diagram describing that OmomycER disrupts
MYC and PKM2 dependent metabolic and tran-
scriptional changes in cancer.
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immunohistochemistry. SALL4 and OCT4 were performed on automated plat-
forms (Ventana) per the manufacturer’s instructions.
Generation of Chimeric Mice
Single-cell suspensions of exponentially growing iPSCs were used for blasto-
cysts injection by the standard procedure. Blastocysts were obtained at day
3.5 of gestation from superovulated albino C57Bl/6J (B6(Cg)-Tyrc-2J/J, Jax #
000058) female mice. For each blastocyst, an average of either 8 or 12 iPSCs
was injected. After injection, blastocysts were returned to optimization me-
dium and placed at 37C until transferred to recipient females. A total of
10–15 injected blastocysts were transferred to each uterine horn of 2.5-day-
postcoitum-pseudopregnant females. Animal studies were approved by insti-
tutional animal care and use committees.
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